Commission authorises 4th vaccine against COVID-19

12/03/2021 News Europe 367 Views
Commission authorises 4th vaccine against COVID-19

On March 11, the European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the fourth COVID-19 vaccine authorised in the EU.

This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States.

The President of the European Commission, Ursula von der Leyen, said: “The Janssen vaccine is the fourth authorised vaccine of the EU’s portfolio and will help us enhance the vaccination campaign in the second quarter of 2021. It only requires a single dose, which takes us another step closer to achieving our collective goal of vaccinating 70% of the adult population by the end of summer.”

Stella Kyriakides, Commissioner for Health and Food Safety, said: “Our portfolio now contains four safe and effective COVID-19 vaccines that we are working tirelessly to deliver to citizens in Europe and beyond as soon as possible. A single dose vaccine can make a difference in the speed of rollout. The entry on the market of the Janssen vaccine ensures that we have access to a total of up to 1.8 billion doses of approved vaccines from different technology platforms – this is key to ensuring access to vaccinations for Europe and our international partners. We will continue to work tirelessly to support vaccine producers and ensure they deliver doses, as agreed in our contracts.”

About author

Related articles